Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
=== MeSH D12.644.400 – neuropeptides === MeSH D12.644.400.070 – angiotensins MeSH D12.644.400.070.075 – angiotensin i MeSH D12.644.400.070.078 – angiotensin ii MeSH D12.644.400.070.080 – angiotensin iii MeSH D12.644.400.085 – bombesin MeSH D12.644.400.090 – bradykinin MeSH D12.644.400.095 – calcitonin MeSH D12.644.400.097 – calcitonin gene-related peptide MeSH D12.644.400.100 – carnosine MeSH D12.644.400.105 – cholecystokinin MeSH D12.644.400.120 – corticotropin MeSH D12.644.400.125 – corticotropin-releasing hormone MeSH D12.644.400.200 – delta sleep-inducing peptide MeSH D12.644.400.235 – fmrfamide MeSH D12.644.400.250 – galanin MeSH D12.644.400.275 – galanin-like peptide MeSH D12.644.400.300 – gastric inhibitory polypeptide MeSH D12.644.400.315 – gastrin-releasing peptide MeSH D12.644.400.320 – gastrins MeSH D12.644.400.340 – glucagon precursors MeSH D12.644.400.340.500 – glucagon MeSH D12.644.400.350 – gonadorelin MeSH D12.644.400.450 – motilin MeSH D12.644.400.460 – melanocyte-stimulating hormones MeSH D12.644.400.460.050 – alpha-msh MeSH D12.644.400.460.075 – beta-msh MeSH D12.644.400.460.115 – gamma-msh MeSH D12.644.400.465 – msh release-inhibiting hormone MeSH D12.644.400.470 – msh-releasing hormone MeSH D12.644.400.500 – neuropeptide y MeSH D12.644.400.525 – neurophysins MeSH D12.644.400.550 – neurotensin MeSH D12.644.400.575 – opioid peptides MeSH D12.644.400.575.180 – dynorphins MeSH D12.644.400.575.241 – endorphins MeSH D12.644.400.575.241.030 – alpha-endorphin MeSH D12.644.400.575.241.080 – beta-endorphin MeSH D12.644.400.575.241.360 – gamma-endorphin MeSH D12.644.400.575.281 – enkephalins MeSH D12.644.400.575.281.075 – enkephalin, ala(2)-mephe(4)-gly(5)- MeSH D12.644.400.575.281.231 – enkephalin, leucine MeSH D12.644.400.575.281.381 – enkephalin, methionine MeSH D12.644.400.575.281.600 – enkephalin, d-penicillamine (2,5)- MeSH D12.644.400.600 – pancreatic polypeptide MeSH D12.644.400.610 – peptide phi MeSH D12.644.400.625 – pituitary adenylate cyclase-activating polypeptide MeSH D12.644.400.640 – pituitary hormone release inhibiting hormones MeSH D12.644.400.645 – pituitary hormone-releasing hormones MeSH D12.644.400.680 – prolactin release-inhibiting hormone MeSH D12.644.400.700 – prolactin-releasing hormone MeSH D12.644.400.702 – thyrotropin-releasing hormone MeSH D12.644.400.705 – secretin MeSH D12.644.400.720 – somatostatin MeSH D12.644.400.740 – somatotropin-releasing hormone MeSH D12.644.400.800 – tachykinins MeSH D12.644.400.800.354 – eledoisin MeSH D12.644.400.800.475 – kassinin MeSH D12.644.400.800.500 – neurokinin a MeSH D12.644.400.800.550 – neurokinin b MeSH D12.644.400.800.625 – physalaemin MeSH D12.644.400.800.750 – substance p MeSH D12.644.400.875 – vasoactive intestinal peptide MeSH D12.644.400.900 – vasopressins MeSH D12.644.400.900.050 – argipressin MeSH D12.644.400.900.400 – lypressin MeSH D12.644.400.900.700 – oxytocin MeSH D12.644.400.900.900 – vasotocin
=== Japan === In Japan, drugs and medical devices are given the designation as an orphan drug or device based on the Act of Securing Quality, Efficacy, Safety of Pharmaceuticals, Medical Devices, Regenerative or Cellular Therapy Products, Gene Therapy Products, and Cosmetics if they are intended for use in less than 50,000 patients in Japan for which there is a high medical need.
==== Engineered OGT ==== Fusion constructs of a nanobody and TPR-truncated OGT allow for proximity-induced protein-specific O-GlcNAcylation in cells. The nanobody may be directed towards protein tags, e.g., GFP, that are fused to the target protein, or the nanobody may be directed towards endogenous proteins. For example, a nanobody recognizing a C-terminal EPEA sequence can direct OGT enzymatic activity to α-synuclein.
=== Pharmacodynamics === Most SNRIs function alongside primary metabolites and secondary metabolites in order to inhibit reuptake of serotonin, norepinepherine, and marginal amounts of dopamine. For example, venlafaxine works alongside its primary metabolite O-desmethylvenlafaxine to strongly inhibit serotonin and norepinephrine reuptake in the brain. The evidence also suggests that dopamine and norepinephrine behave in a co-transportational manner, due to the inactivation of dopamine by norepinephrine reuptake in the frontal cortex, an area of the brain largely lacking in dopamine transporters. This effect of SNRIs results in increased dopamine neurotransmission, in addition to the increases in serotonin and norepinephrine activity. Furthermore, because SNRIs are extremely selective, they have no measurable effects on other, unintended receptors, in contrast to monoamine oxidase inhibition. Pharmaceutical tests have determined that use of both SNRIs or SSRIs can generate significant anti-inflammatory action on microglia, as well.
By 1992, at least thirty academic research teams globally were working to achieve a total synthesis of this natural product, with the synthesis proceeding from simple natural products and other readily available starting materials. This total synthesis effort was motivated primarily by the desire to generate new chemical understanding, rather than with an expectation of the practical commercial production of paclitaxel. The first laboratories to complete the total synthesis from much less complex starting materials were the research groups of Robert A. Holton, who had the first article to be accepted for publication, and of K. C. Nicolaou who had the first article to appear in print (by a week, on 7 February 1994). Though the Holton submission preceded the Nicolaou by a month (21 December 1993 versus 24 January 1994), the near coincidence of the publications arising from each of these massive, multiyear efforts—11–18 authors appearing on each of the February 1994 publications—has led the ending of the race to be termed a "tie" or a "photo finish", though each group has argued that their synthetic strategy and tactics were superior. As of 2006, five additional research groups had reported total syntheses of paclitaxel: Wender et al. in 1997, and Kuwajima et al. and Mukaiyama et al. in 1998 with further linear syntheses, and Danishefsky et al. in 1996 and Takahashi et al. in 2006 with further convergent syntheses.
Sources: en.wikipedia.org
The UK's light-touch regulatory approach has drawn criticism for potentially leaving the public inadequately protected. Organisations like the Ada Lovelace Institute argue for a statutory AI Bill to mandate pre-deployment testing and empower regulators, citing public polling that strongly supports independent regulation. The impact of AI on the labour market is another major concern. Reports suggest that up to three million UK jobs could be displaced by 2035, with lower-skilled and entry-level positions particularly vulnerable. Trade unions, including the Trades Union Congress and Prospect, have raised alarms about the rise of algorithmic management and workplace surveillance, calling for a "pro-worker" AI strategy and the right to disconnect. Furthermore, there are concerns about the UK's dependence on US technology infrastructure, which some argue threatens economic competitiveness and national security, leading to calls for greater "digital sovereignty". The UK faces intense debate over AI developers training models on copyrighted material. Following strong opposition from the creative sector and trade unions, the government abandoned a 2024 proposal that would have allowed broad text and data mining (TDM) with only an "opt-out" for creators. Conversely, academia and libraries argue that narrow TDM exceptions restrict research. They criticise major publishers for charging universities to access research while simultaneously selling that same data to commercial AI developers, often steering authors towards restrictive licences to retain exclusive commercial rights.
=== Generic names === Oxandrolone is the generic name of the drug and its INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name, USPTooltip United States Pharmacopeia, BANTooltip British Approved Name, DCFTooltip Dénomination Commune Française, DCITTooltip Denominazione Comune Italiana, and JANTooltip Japanese Accepted Name, while ossandrolone is or was formerly the DCITTooltip Denominazione Comune Italiana.
Californium-252 (Cf-252, 252Cf) undergoes spontaneous fission with a branching ratio of 3.09% and is used in small neutron sources. Fission neutrons have an energy range of 0 to 13 MeV with a mean value of 2.3 MeV and a most probable value of 1 MeV. This isotope produces high neutron emissions and has a number of uses in industries such as nuclear energy, medicine, and petrochemical exploration.
=== Cancer === In vitro, when cells approach the Hayflick limit, the time to senescence can be extended by inactivating the tumor suppressor proteins p53 and Retinoblastoma protein (pRb). Cells that have been so-altered eventually undergo an event termed a "crisis" when the majority of the cells in the culture die. Sometimes, a cell does not stop dividing once it reaches a crisis. In a typical situation, the telomeres are shortened and chromosomal integrity declines with every subsequent cell division. Exposed chromosome ends are interpreted as double-stranded breaks (DSB) in DNA; such damage is usually repaired by reattaching the broken ends together. When the cell does this due to telomere-shortening, the ends of different chromosomes can be attached to each other. This solves the problem of lacking telomeres, but during cell division anaphase, the fused chromosomes are randomly ripped apart, causing many mutations and chromosomal abnormalities. As this process continues, the cell's genome becomes unstable. Eventually, either fatal damage is done to the cell's chromosomes (killing it via apoptosis), or an additional mutation that activates telomerase occurs. With telomerase activation some types of cells and their offspring become immortal (bypass the Hayflick limit), thus avoiding cell death as long as the conditions for their duplication are met. Many cancer cells are considered 'immortal' because telomerase activity allows them to live much longer than any other somatic cell, which, combined with uncontrollable cell proliferation is why they can form tumors.
Hummingbirds resemble sunbirds. The former live in the Americas and belong to an order or superorder including the swifts, while the latter live in Africa and Asia and are a family in the order Passeriformes. Also the nectar-feeding Hawaiian honeycreepers resemble the two and differs from other honeycreeper. Flightlessness has evolved in many different birds independently. However, taking this to a greater extreme, the terror birds, Gastornithiformes and dromornithids (ironically all extinct) all evolved the similar body shape (flightlessness, long legs, long necks, big heads), yet none of them were closely related. They also share the trait of being giant, flightless birds with vestigial wings, long legs, and long necks with the ratites, although they are not related. Certain longclaws (Macronyx) and meadowlarks (Sturnella) have essentially the same striking plumage pattern. The former inhabit Africa and the latter the Americas, and they belong to different lineages of Passerida. While they are ecologically quite similar, no satisfying explanation exists for the convergent plumage; it is best explained by sheer chance. Resemblances between swifts and swallows is due to convergent evolution. The chimney swift was originally identified as chimney swallow (Hirundo pelagica) by Carl Linnaeus in 1758, before being moved to the swift genus Chaetura by James Francis Stephens in 1825.
Sources: en.wikipedia.org
=== Newborn screening === Several countries test all newborns for SCID as a part of routine newborn screening. A measure using real-time quantitative PCR of the blood concentration of T-cell receptor excision circles (TRECs), which are reduced in SCID, is the method used to screen all U.S. newborns for SCID. As of September 2022, the known percentage of newborns screened has increased throughout the world with 100% in the United States, 100% in Australia, 78% in Europe, 32% in Latin America, 26% in the Middle East and North Africa, 13% in Asia-Pacific, and 0% in Central America. The introduction of newborn screenings and genetic testing in many countries has allowed early detection and treatment before the development of severe infections, which progressively improved the five-year survival rate for newborns with SCID to around 90%.
==== Cardiomyopathies ==== Cardiomyopathies are diseases affecting the muscle of the heart. Some cause abnormal thickening of the heart muscle (hypertrophic cardiomyopathy), some cause the heart to abnormally expand and weaken (dilated cardiomyopathy), some cause the heart muscle to become stiff and unable to fully relax between contractions (restrictive cardiomyopathy) and some make the heart prone to abnormal heart rhythms (arrhythmogenic cardiomyopathy). These conditions are often genetic and can be inherited, but some such as dilated cardiomyopathy may be caused by damage from toxins such as alcohol. Some cardiomyopathies such as hypertrophic cardiomopathy are linked to a higher risk of sudden cardiac death, particularly in athletes. Many cardiomyopathies can lead to heart failure in the later stages of the disease.
is the cross-sectional area, which can often be reasonably approximated as a rectangle with the characteristic width and depth. This absorbs velocity, width, and depth. We define stream power per unit channel length, so that term goes to 1, and the derivation is complete.
== Stem cell aging == Intestinal stem cell aging has been studied in Drosophila as a model for understanding the biology of stem cell/niche aging. Using knockdown mutants defective in various genes that function in the DNA damage response in enterocytes, it was shown that deficiency in the DNA damage response accelerates intestinal stem cell aging, thus providing a better understanding of the molecular mechanisms of this aging process.
Most infants with CMD will display some progressive muscle weakness or muscle wasting (atrophy), although there can be different degrees and symptoms of severeness of progression. The weakness is indicated as hypotonia, or lack of muscle tone, which can make an infant seem unstable. Eventually, most patients develop joint contractures or fixed joint deformities. Children may be slow with their motor skills; such as rolling over, sitting up or walking, or may not even reach these milestones of life. Some of the rarer forms of CMD can result in significant learning disabilities.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.